Literature DB >> 26374223

Cardiovascular Magnetic Resonance Imaging clarifies cardiac pathophysiology in early, asymptomatic diffuse systemic sclerosis.

Sophie I Mavrogeni1, Konstantinos Bratis, Georgia Karabela, George Spiliotis, Kees van Wijk, David Hautemann, Johan H C Reiber, Loukia Koutsogeorgopoulou, George Markousis-Mavrogenis, Genovefa Kolovou, Efthymios Stavropoulos.   

Abstract

BACKGROUND: Myopericardial inflammation, perfusion's defects and fibrosis are major causes of cardiac disease in scleroderma (SSc). We hypothesized that using inflammation and stress perfusion-fibrosis cardiovascular magnetic resonance (CMR), we can identify the pathophysiology of heart disease in asymptomatic diffuse SSc. PATIENTS-
METHODS: 46 recently diagnosed, asymptomatic patients with diffuse SSc had a CMR examination using a 1.5T system. ECG gated breath hold cine and short tau inversion recovery (STIR) T2 images were initially acquired. If T2 ratio<2 a stress perfusion-fibrosis protocol was applied. If T2>2 a myocarditis protocol including early (EGE) and late (LGE) gadolinium imaging was applied. SSc patients' results were compared with age and sex-matched controls and patients with coronary artery disease (CAD).
RESULTS: In 2/46 SSc with T2 ratio>2, the myocarditis protocol was positive for acute myocardial inflammation, who developed clinical signs of acute myocarditis shortly after the CMR evaluation. In the rest 44/46 with T2 ratio<2 the stress perfusion-fibrosis CMR identified a significant reduction in Myocardial Perfusion Reserve Index (MPRI) compared with matched controls (0.6±0.4 vs 3.2±0.8, p<0.001), but not with CAD (0.6±0.4 vs 0.86±0.46, p=NS) and correlated only with the presence of digital ulcers (p<0.05). The scar was diffused and greater compared to controls, but did not differ from that assessed in CAD. Two years follow up, available in 11/44 SSc, showed further asymptomatic MPRI deterioration in all and diffuse subendocardial LGE in 8/11, without any change in LV, RV volumes and ejection fractions.
CONCLUSION: CMR may reveal severe cardiac involvement in early, asymptomatic diffuse SSc with normal routine cardiac evaluation, presenting either as myocardial inflammation or as severe reduction of MPRI and diffuse fibrosis with further deterioration in the long term follow up.

Entities:  

Mesh:

Year:  2015        PMID: 26374223     DOI: 10.2174/1871528114666150916112551

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  23 in total

1.  Predictors of subclinical systemic sclerosis primary heart involvement characterised by microvasculopathy and myocardial fibrosis.

Authors:  Raluca B Dumitru; Lesley-Anne Bissell; Bara Erhayiem; Graham Fent; Ananth Kidambi; Peter Swoboda; Giuseppina Abignano; Helena Donica; Agata Burska; John P Greenwood; John Biglands; Francesco Del Galdo; Sven Plein; Maya H Buch
Journal:  Rheumatology (Oxford)       Date:  2021-06-18       Impact factor: 7.580

Review 2.  A critical view on cardiovascular risk in systemic sclerosis.

Authors:  Antonios Psarras; Stergios Soulaidopoulos; Alexandros Garyfallos; George Kitas; Theodoros Dimitroulas
Journal:  Rheumatol Int       Date:  2016-07-12       Impact factor: 2.631

Review 3.  Can cardiovascular magnetic resonance prompt early cardiovascular/rheumatic treatment in autoimmune rheumatic diseases? Current practice and future perspectives.

Authors:  Sophie I Mavrogeni; Petros P Sfikakis; Theodoros Dimitroulas; Loukia Koutsogeorgopoulou; Gikas Katsifis; George Markousis-Mavrogenis; Genovefa Kolovou; George D Kitas
Journal:  Rheumatol Int       Date:  2018-03-07       Impact factor: 2.631

Review 4.  Chronic inflammatory diseases, myocardial function and cardioprotection.

Authors:  Antigone Lazou; Ignatios Ikonomidis; Monika Bartekova; Theodora Benedek; George Makavos; Dimitra Palioura; Hector Cabrera Fuentes; Ioanna Andreadou
Journal:  Br J Pharmacol       Date:  2020-02-08       Impact factor: 8.739

Review 5.  Progress in Understanding, Diagnosing, and Managing Cardiac Complications of Systemic Sclerosis.

Authors:  George Hung; Valentina Mercurio; Steven Hsu; Stephen C Mathai; Ami A Shah; Monica Mukherjee
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

Review 6.  Update on assessment and management of primary cardiac involvement in systemic sclerosis.

Authors:  Vasiliki-Kalliopi Bournia; Christos Tountas; Athanase D Protogerou; Stylianos Panopoulos; Sophie Mavrogeni; Petros P Sfikakis
Journal:  J Scleroderma Relat Disord       Date:  2018-04-04

7.  Replacement myocardial fibrosis at the site of late gadolinium enhancement on magnetic resonance imaging in a patient with diffuse cutaneous systemic sclerosis: An autopsy report.

Authors:  Atsushi Noguchi; Ichizo Tsujino; Noriko Oyama-Manabe; Mishie Tanino
Journal:  J Cardiol Cases       Date:  2017-05-13

8.  Diffuse cardiac fibrosis quantification in early systemic sclerosis by magnetic resonance imaging and correlation with skin fibrosis.

Authors:  Daniel C Lee; Monique E Hinchcliff; Roberto Sarnari; Madeline M Stark; Jungwha Lee; Kimberly Koloms; Aileen Hoffmann; Mary Carns; Anjali Thakrar; Kathleen Aren; John Varga; Alejandro Aquino; James C Carr; Brandon C Benefield; Sanjiv J Shah
Journal:  J Scleroderma Relat Disord       Date:  2018-04-12

9.  Association Between Impaired Myocardial Flow Reserve on 82Rubidium Positron Emission Tomography Imaging and Adverse Events in Patients With Autoimmune Rheumatic Disease.

Authors:  Attila Feher; Nabil E Boutagy; Evangelos K Oikonomou; Yi-Hwa Liu; Edward J Miller; Albert J Sinusas; Monique Hinchcliff
Journal:  Circ Cardiovasc Imaging       Date:  2021-09-10       Impact factor: 8.589

Review 10.  Cardiac MRI in Autoimmune Diseases: Where Are We Now?

Authors:  Natalia G Vallianou; Eleni Geladari; Fotis Panagopoulos; Maria Kalantzi
Journal:  Curr Cardiol Rev       Date:  2021
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.